Increased serum levels of lipogenic enzymes in patients with severe liver steatosis

Maria Notarnicola, Giovanni Misciagna, Valeria Tutino, Marisa Chiloiro, Alberto Ruben Osella, Vito Guerra, Caterina Bonfiglio, Maria Gabriella Caruso

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Lipid metabolism is altered in subjects with liver steatosis. FAS is a key enzyme in de novo lipogenesis and both FAS gene expression and enzymatic activity are primarily regulated by metabolic signals in the liver. Lipoprotein lipase (LPL), the rate-limiting enzyme for the hydrolysis of core triglycerides, plays a pivotal role in lipid metabolism. This study aims to investigate if circulating levels of FAS and LPL could be clinically associated with liver steatosis. Methods. In this work, we present data obtained from a subsample of 94 subjects with liver steatosis enrolled by NUTRIEPA study, a nutritional trial in subjects with liver steatosis. Serum levels of FAS protein and LPL activity were evaluated by ELISA test and by a fluorescent method, respectively. The diagnosis and the degree of liver steatosis were based on laboratory and ecographic measurements. Statistical methods included Kruskal-Wallis analysis of variance and Wilcoxon signed-rank test, where appropriate. The χ2 test has been performed to analyse categorical variables. Results: The subjects with severe steatosis had significantly higher serum levels of FAS protein and LPL activity compared to subjects with mild and moderate liver steatosis. Moreover, a positive trend in serum levels of FAS expression from lower to higher degree of steatosis was also detected. Conclusions: We describe a relationship between human liver steatosis and elevated levels of circulating lipogenic enzymes. Increased serum levels of FAS expression and LPL activity could be considered a marker of severe liver steatosis.

Original languageEnglish
Article number145
JournalLipids in Health and Disease
Volume11
DOIs
Publication statusPublished - 2012

Fingerprint

Fatty Liver
Liver
Lipoprotein Lipase
Enzymes
Serum
Lipid Metabolism
Lipogenesis
Nonparametric Statistics
Analysis of variance (ANOVA)
Gene expression
Analysis of Variance
Triglycerides
Proteins
Hydrolysis
Enzyme-Linked Immunosorbent Assay
Statistical methods
Gene Expression

Keywords

  • Enzyme activity
  • Fatty acid synthase
  • Lipoprotein lipase
  • Liver steatosis

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Increased serum levels of lipogenic enzymes in patients with severe liver steatosis. / Notarnicola, Maria; Misciagna, Giovanni; Tutino, Valeria; Chiloiro, Marisa; Osella, Alberto Ruben; Guerra, Vito; Bonfiglio, Caterina; Caruso, Maria Gabriella.

In: Lipids in Health and Disease, Vol. 11, 145, 2012.

Research output: Contribution to journalArticle

@article{39e6737cc018442a859d10749aab6105,
title = "Increased serum levels of lipogenic enzymes in patients with severe liver steatosis",
abstract = "Background: Lipid metabolism is altered in subjects with liver steatosis. FAS is a key enzyme in de novo lipogenesis and both FAS gene expression and enzymatic activity are primarily regulated by metabolic signals in the liver. Lipoprotein lipase (LPL), the rate-limiting enzyme for the hydrolysis of core triglycerides, plays a pivotal role in lipid metabolism. This study aims to investigate if circulating levels of FAS and LPL could be clinically associated with liver steatosis. Methods. In this work, we present data obtained from a subsample of 94 subjects with liver steatosis enrolled by NUTRIEPA study, a nutritional trial in subjects with liver steatosis. Serum levels of FAS protein and LPL activity were evaluated by ELISA test and by a fluorescent method, respectively. The diagnosis and the degree of liver steatosis were based on laboratory and ecographic measurements. Statistical methods included Kruskal-Wallis analysis of variance and Wilcoxon signed-rank test, where appropriate. The χ2 test has been performed to analyse categorical variables. Results: The subjects with severe steatosis had significantly higher serum levels of FAS protein and LPL activity compared to subjects with mild and moderate liver steatosis. Moreover, a positive trend in serum levels of FAS expression from lower to higher degree of steatosis was also detected. Conclusions: We describe a relationship between human liver steatosis and elevated levels of circulating lipogenic enzymes. Increased serum levels of FAS expression and LPL activity could be considered a marker of severe liver steatosis.",
keywords = "Enzyme activity, Fatty acid synthase, Lipoprotein lipase, Liver steatosis",
author = "Maria Notarnicola and Giovanni Misciagna and Valeria Tutino and Marisa Chiloiro and Osella, {Alberto Ruben} and Vito Guerra and Caterina Bonfiglio and Caruso, {Maria Gabriella}",
year = "2012",
doi = "10.1186/1476-511X-11-145",
language = "English",
volume = "11",
journal = "Lipids in Health and Disease",
issn = "1476-511X",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Increased serum levels of lipogenic enzymes in patients with severe liver steatosis

AU - Notarnicola, Maria

AU - Misciagna, Giovanni

AU - Tutino, Valeria

AU - Chiloiro, Marisa

AU - Osella, Alberto Ruben

AU - Guerra, Vito

AU - Bonfiglio, Caterina

AU - Caruso, Maria Gabriella

PY - 2012

Y1 - 2012

N2 - Background: Lipid metabolism is altered in subjects with liver steatosis. FAS is a key enzyme in de novo lipogenesis and both FAS gene expression and enzymatic activity are primarily regulated by metabolic signals in the liver. Lipoprotein lipase (LPL), the rate-limiting enzyme for the hydrolysis of core triglycerides, plays a pivotal role in lipid metabolism. This study aims to investigate if circulating levels of FAS and LPL could be clinically associated with liver steatosis. Methods. In this work, we present data obtained from a subsample of 94 subjects with liver steatosis enrolled by NUTRIEPA study, a nutritional trial in subjects with liver steatosis. Serum levels of FAS protein and LPL activity were evaluated by ELISA test and by a fluorescent method, respectively. The diagnosis and the degree of liver steatosis were based on laboratory and ecographic measurements. Statistical methods included Kruskal-Wallis analysis of variance and Wilcoxon signed-rank test, where appropriate. The χ2 test has been performed to analyse categorical variables. Results: The subjects with severe steatosis had significantly higher serum levels of FAS protein and LPL activity compared to subjects with mild and moderate liver steatosis. Moreover, a positive trend in serum levels of FAS expression from lower to higher degree of steatosis was also detected. Conclusions: We describe a relationship between human liver steatosis and elevated levels of circulating lipogenic enzymes. Increased serum levels of FAS expression and LPL activity could be considered a marker of severe liver steatosis.

AB - Background: Lipid metabolism is altered in subjects with liver steatosis. FAS is a key enzyme in de novo lipogenesis and both FAS gene expression and enzymatic activity are primarily regulated by metabolic signals in the liver. Lipoprotein lipase (LPL), the rate-limiting enzyme for the hydrolysis of core triglycerides, plays a pivotal role in lipid metabolism. This study aims to investigate if circulating levels of FAS and LPL could be clinically associated with liver steatosis. Methods. In this work, we present data obtained from a subsample of 94 subjects with liver steatosis enrolled by NUTRIEPA study, a nutritional trial in subjects with liver steatosis. Serum levels of FAS protein and LPL activity were evaluated by ELISA test and by a fluorescent method, respectively. The diagnosis and the degree of liver steatosis were based on laboratory and ecographic measurements. Statistical methods included Kruskal-Wallis analysis of variance and Wilcoxon signed-rank test, where appropriate. The χ2 test has been performed to analyse categorical variables. Results: The subjects with severe steatosis had significantly higher serum levels of FAS protein and LPL activity compared to subjects with mild and moderate liver steatosis. Moreover, a positive trend in serum levels of FAS expression from lower to higher degree of steatosis was also detected. Conclusions: We describe a relationship between human liver steatosis and elevated levels of circulating lipogenic enzymes. Increased serum levels of FAS expression and LPL activity could be considered a marker of severe liver steatosis.

KW - Enzyme activity

KW - Fatty acid synthase

KW - Lipoprotein lipase

KW - Liver steatosis

UR - http://www.scopus.com/inward/record.url?scp=84867900806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867900806&partnerID=8YFLogxK

U2 - 10.1186/1476-511X-11-145

DO - 10.1186/1476-511X-11-145

M3 - Article

C2 - 23110339

AN - SCOPUS:84867900806

VL - 11

JO - Lipids in Health and Disease

JF - Lipids in Health and Disease

SN - 1476-511X

M1 - 145

ER -